HIF1A and melanoma: Moreover, the treatment of melanoma-bearing mice with Acriflavine, which is reported to prevent the dimerization between HIF-1α and HIF-1β [147], led to an improvement in immunotherapy based on TRP-2 peptide vaccination and anti-PD-1 antibody [40].